PARK RIDGE, N.J. - (Business Wire) M3 USA, together with Bristol-Myers Squibb (NYSE: BMY), is launching a pilot program to oncologists using M3’s next-generation eLearning and eMarketing solution. The solution – M3 Messages™ – takes a new approach to developing valuable, long-term, online connections that help doctors stay current on advances in oncology. The M3 Messages solution opens a relationship-based communication link for physicians and companies that allows for informative dialogues about oncology medicines. According to Stephen Smith, Chief Marketing Officer for M3 USA, the approach helps to make important medical information available to oncologists in new, more interactive ways that medical professionals are requesting.
M3 Messages’ potential to change pharmaceutical communications in the e-space is significant. “This model is well-established in Japan, and now, with half of US oncologists using our product, and with psychiatry, cardiology, and other specialties coming on board, we can create the same dynamic here in the US,” says Aki Tomaru, CEO.
About M3 Messages™
M3 Messages™ creates a personalized, relationship-based, weekly connection between pharmaceutical brands and their target physicians. M3 Messages is tightly integrated into MDLinx Oncology, a specialty portal already used by 50% of US oncologists and hematologists.
About M3 USA Corporation
M3 USA Corporation is a Sony Group Company. Its parent, So-net M3, Inc. in Japan is the leading provider of online pharmaceutical promotion solution in Japan. M3 Messages™ has been well adopted in Japan by over 50 pharmaceutical brands and generating over 3 million online interactions between brands and their target physicians on monthly basis. MDLinx.com is a property of M3 USA Corporation.
M3 USA Corporation
Stephen Smith, 202-293-2288
ssmith@usa.m3.com
